Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA).

ABSTRACT: Prevention and rehabilitation of hearing loss and tinnitus, the two most commonly awarded service-connected disabilities, are high priority initiatives in the Department of Veterans Affairs (VA). At least 4,000 Veterans, most with significant hearing loss, will receive cisplatin this year, with more than half sustaining permanent hearing shift and nearly 40% developing new tinnitus. With improved survivability following cancer treatment, Veterans treated with cisplatin are approached with the dual goals of effective treatment and preserved quality of life. This article describes COMP-VA, a comprehensive ototoxicity monitoring program developed for VA patients receiving cisplatin. The program includes an individualized pretreatment prediction model that identifies the likelihood of hearing

SUBMITTER: Konrad-Martin D 

PROVIDER: S-EPMC4635678 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature